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Supplementary Table 1. Characteristics of fracture healing by treatment group 
 





Week 2 (202) (189)  
Fracture healed 8 (4.0%) 13 (6.9%) 0.15 
Endosteal healed 27 (13.4%) 35 (18.5%)  
Organised trabecular bridging 158 (78.2%) 151 (79.9%)  
 
 
Number of cortices bridged 
0 67 (33.2%) 54 (28.6%)  
1 54 (26.7%) 45 (23.8%)  
2 45 (22.3%) 56 (29.6%)  
3 25 (12.4%) 22 (11.6%)  
4 11 (5.4%) 12 (6.3%)  
Week 4 (202) (187)  
Fracture healed 49 (22.8%) 54 (26.2%) 0.31 
Endosteal healed 48 (23.8%) 52 (27.8%)  
Organised trabecular bridging 71 (35.1%) 78 (41.7%)  
Number of cortices bridged 180 (89.1%) 167 (89.3%)  
 
 
Number of cortices bridged 
0 31 (15.4%) 35 (18.7%)  
1 26 (12.9%) 27 (14.4%)  
2 47 (23.4%) 40 (21.4%)  
3 49 (24.2%) 46 (24.6%)  
4 48 (23.9%) 39 (20.9%)  
Week 6 (202) (187)  
Fracture healed 86 (44.6%) 80 (44.2%) 0.88 
Endosteal healed 110 (57.0%) 109 (60.2%)  
Organised trabecular bridging  179 (92.7%) 173 (95.6%)  
 
 
Number of cortices bridged1 
0 7 (3.6%) 14 (7.7%)  
1 15 (7.8%) 11 (6.1%)  
2 42 (21.8%) 36 (19.9%)  
3 60 (31.1%) 48 (26.5%)  
4 69 (35.8%) 72 (39.8%)  
Week 8 (193) (181)  
Fracture healed 121 (61.7%) 103 (56.3%) 0.19 
Endosteal healed 139 (70.9%) 127 (69.4%)  
Organised trabecular bridging 192 (98.0%) 176 (96.2%)  
 
 
Number of cortices bridged 
0 6 (3.1%) 8 (4.4%)  
1 12 (6.1%) 13 (7.1%)  
2 24 (12.2%) 19 (10.4%)  
3 55 (28.1%) 38 (20.8%)  
4 99 (50.5%) 105 (57.4%)  
Values are numbers (%). The p=values were generated using logistic regression with 
covariates of age, ulnar variance at baseline, study site, gender, fracture status and 
comminution at baseline. 1 Data on cortical bridging was available on 201 subjects in the 
alendronic acid group  
Supplementary table 2. Patient centred outcomes by treatment group  
 





Week 2 (200) (189)  
Pain score 3.5 ± 2.2 3.4 ±2.3 0.98 
DASH score 48.9 ± 17.4 49.8 ±18.1 0.57 
Week 4 (201) (186)  
Pain score (with imputation) 3.0 ± 2.0 2.7 ± 2.1 0.13 
Pain score  3.0 ± 2.0 2.7 ± 2.2 0.26 
DASH score  (with imputation) 40.8 ± 18.5 39.8 ± 19.2 0.57 
DASH score 1 40.7 ± 19.1 39.7 ± 19.7 0.62 
Week 8 (199) (183)  
Pain score 2.4 ± 2.1 2.4 ±2.2 0.98 
DASH score 25.7 ± 16.9 25.4 ±20.2 0.57 
Grip strength deficit (Kg) 2 12.0 ± 7.8 12.1 ± 7.7 0.96 
Week 26 (198) (182)  
Pain score 1.3 ± 1.9 1.3 ± 1.8 0.96 
DASH score 12.7 ± 14.7 13.3 ± 16.0 0.65 
Grip strength deficit (Kg) 2 6.0 ± 5.2 5.8 ±  5.9 0.86 
Flexion deficit 3 13.3 ± 14.2 14.5 ± 13.4 0.32 
Extension deficit 5.7 ± 11.3 6.6 ± 12.3 0.48 
Supination deficit 8.7 ± 14.1 8.4 ± 15.1 0.72 
Pronation deficit 3.0 ± 10.8 3.7 ± 25.2  0.75 
 
Values are means ±. The p=values were generated using logistic regression with covariates of 
age, ulnar variance at baseline, study site, gender, fracture status and comminution at 
baseline. 1 DASH score was available in 200 subjects in the alendronic acid group and 198 in 
the placebo group; 2 Grip strength deficit was available in 196 of the alendronic acid group at 
these time points;  4 Data on flexion, extension, supination and pronation deficit was available 
on 196 of the alendronic acid group and 181 of the placebo group.  
  
Supplementary Table 3. Other reason for non-enrolment into FAB study 
 
Reason Number 
Reason not recorded 226 
Did not attend clinic 170 
Unable to make contact 22 
Patient going on holiday 105 
Medical issues 133 
Social issues 69 
Conflicting trial 13 




Supplementary Figure 1. Time to fracture healing 
 
 
